VVTMF (VVT Med) YoY EBITDA Growth: -33.33% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VVTMF VVT Med Inc VVTMF
2 GF Score
Price $0.16
! 5 Warning Signs
View Full Analysis

What is VVT Med YoY EBITDA Growth?

VVT Med VVTMF 2 YoY EBITDA Growth is -33.33% as of Mar. 2026. GuruFocus rates VVTMF with a GF Score™ of 2/100. The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. VVT Med's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -33.33%.

VVT Med's EBITDA per Share for the three months ended in Mar. 2026 was $-0.01.

VVT Med YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for VVT Med's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VVT Med YoY EBITDA Growth Chart

VVT Med Annual Data
Trend Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 23.53 69.23 -750.00

VVT Med Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -500.00 0.00 -433.33 -366.67 -33.33
VVTMF
2GF Score
VVT Med Inc VVTMF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VVT Med YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

VVT Med's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.068--0.008)/ | -0.008 |
=-750.00 %

VVT Med's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.008--0.006)/ | -0.006 |
=-33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -33.33% mean?
VVT Med (VVTMF) has a YoY EBITDA Growth of -33.33% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for VVT Med and its competitors.
Is VVT Med's YoY EBITDA Growth too high?
VVT Med's current YoY EBITDA Growth is -33.33%. Overall, VVT Med has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does VVT Med's YoY EBITDA Growth compare to ABT and SYK?
VVT Med's YoY EBITDA Growth of -33.33% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for VVT Med and its competitors. VVT Med's current YoY EBITDA Growth is -33.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VVT Med stock overvalued right now?
VVT Med (VVTMF) has a current YoY EBITDA Growth of -33.33%. The current YoY EBITDA Growth is -33.33%. VVT Med's overall GF Score™ is 2/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For VVT Med (VVTMF), the current YoY EBITDA Growth is -33.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VVT Med Business Description

Other Exchanges VVTM:Canada
Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT's research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
2GF Score

Get the complete analysis for VVTMF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price